Alan J. Buckler

Alan joined Triplet Therapeutics, Inc. as Chief Scientific Office in August 2020. Previously, he served as Chief Scientific Officer of Scholar Rock where he was responsible for research, discovery, preclinical development, and manufacturing of the company’s novel antibody-based therapeutics. Prior to joining Scholar Rock, Alan held senior level research positions in Biogen and Novartis, where he led both target validation and drug discovery efforts for multiple therapeutic modalities. Prior to Novartis, Alan served as the Chief Scientific Officer of Ardais Corporation and as Vice President of Molecular Genetics at Sequana Therapeutics/Axys Pharmaceuticals from. Prior to joining industry, Alan served on the Neurology faculty of Massachusetts General Hospital and Harvard Medical School, where his collaborative focus was on the genetics of cancer and rare diseases, including Huntington’s Disease and Myotonic Dystrophy. Alan received his A.B. in Biology from the University of Chicago, Ph.D. in Microbiology from the Boston University School of Medicine and completed his post-doctoral training at the Center for Cancer Research, Massachusetts Institute of Technology.